MEK抑制剂在白血病治疗中的研究进展

The progress of MEK inhibitor on the therapy of leukemia

随着肿瘤发病机制及分子生物学研究的深入,近年来分子靶向药物治疗取得了喜人的进展。特异靶向肿瘤异常信号通路关键分子的抑制剂是当前新药开发的重点之一。RAS/RAF/MEK/ERK(MAPK)信号通路在肿瘤细胞的增殖、存活、侵袭和血管再生等方面发挥着重要作用。许多肿瘤中存在着该通路的异常激活。MAPK的异常活化在血液恶性疾病中同样意义重大。作为MAPK信号通路上的关键分子,MEK在疾病发生中的关键地位显而易见。本文就RAS/RAF/MEK/ERK信号通路上的关键分子MEK展开,主要阐述近年来国内外有关MEK抑制剂在白血病治疗方向上的研究进展。

With the further study of the tumor pathogenesis and molecular biology research,lots of achievements have been attained in recent years. The inhibitors targeting the key opponents in deregulated signal pathway is the one of the highlights in new drug development. RAS/RAF/MEK/ERK(MAPK) signal pathway plays an important role in the regulation of tumor biological behaviors such as proliferation, survival and migration. The hyperactivation of this signal pathway is commonly found in solid tumors as well as hematopoietic malignancies. As a key point of MAPK signal pathway, targeting MEK seems to be a good choice. In this paper, the progress of MEK inhibitor on the therapy of leukemia will be discussed.